{"name":"TolerogenixX GmbH","slug":"tolerogenixx-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MIC","genericName":"MIC","slug":"mic","indication":"Treatment of infections caused by susceptible bacteria, including pneumonia, skin and soft tissue infections, and urinary tract infections","status":"marketed"}]}],"pipeline":[{"name":"MIC","genericName":"MIC","slug":"mic","phase":"marketed","mechanism":"MIC is a broad-spectrum antibiotic that inhibits cell wall synthesis by binding to the bacterial cell wall.","indications":["Treatment of infections caused by susceptible bacteria, including pneumonia, skin and soft tissue infections, and urinary tract infections"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPazl5N24yUDBDYUliMnNaR1JHVDNGSl9XZ0VfZUdoTTBvMEV1ZW01ODhlWU01QjFMZEN0bDVYSS11blNyTjhaZGplNkFEWTNVNjJuaXgxSHY1bGRxVlg3cjBsQWVNV0lieDZXazNKaXJtcVVHcEw5UEs5dWNPejNEWW1qSlI5dHVQ?oc=5","date":"2023-07-07","type":"trial","source":"labiotech.eu","summary":"TolerogenixX expands trial and closes €12M financing - labiotech.eu","headline":"TolerogenixX expands trial and closes €12M financing","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}